

# Daniele Focosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1826144/publications.pdf>

Version: 2024-02-01

204  
papers

5,438  
citations

109321

35  
h-index

102487

66  
g-index

233  
all docs

233  
docs citations

233  
times ranked

7761  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. <i>Blood</i> , 2009, 113, 4834-4840.	1.4	829
2	Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Lancet Oncology</i> , The, 2009, 10, 816-824.	10.7	433
3	CD57+ T lymphocytes and functional immune deficiency. <i>Journal of Leukocyte Biology</i> , 2009, 87, 107-116.	3.3	217
4	Torquetenovirus: the human virome from bench to bedside. <i>Clinical Microbiology and Infection</i> , 2016, 22, 589-593.	6.0	172
5	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013, 4, 502-530.	1.8	152
6	Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. <i>EBioMedicine</i> , 2022, 75, 103788.	6.1	149
7	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. <i>Reviews in Medical Virology</i> , 2021, 31, e2231.	8.3	128
8	Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. <i>MAbs</i> , 2020, 12, 1854149.	5.2	126
9	Are we overestimating the loss of beta cells in type 2 diabetes?. <i>Diabetologia</i> , 2014, 57, 362-365.	6.3	115
10	Monoclonal antibody therapies against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e311-e326.	9.1	114
11	Convalescent Plasma Therapy for COVID-19: State of the Art. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	13.6	94
12	Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. <i>Journal of Clinical Virology</i> , 2010, 47, 189-192.	3.1	92
13	Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. <i>Annals of Hematology</i> , 2008, 87, 405-412.	1.8	76
14	Lithium and hematology: established and proposed uses. <i>Journal of Leukocyte Biology</i> , 2009, 85, 20-28.	3.3	75
15	Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab. <i>Reviews in Medical Virology</i> , 2019, 29, e2077.	8.3	74
16	Laparoscopic Robot-Assisted Pancreas Transplantation. <i>Transplantation</i> , 2012, 93, 201-206.	1.0	73
17	Short-term kinetics of torque teno virus viraemia after induction immunosuppression confirm T lymphocytes as the main replication-competent cells. <i>Journal of General Virology</i> , 2015, 96, 115-117.	2.9	73
18	Torque Teno Virus Viremia Correlates With Intensity of Maintenance Immunosuppression in Adult Orthotopic Liver Transplant. <i>Journal of Infectious Diseases</i> , 2014, 210, 667-668.	4.0	70

#	ARTICLE	IF	CITATIONS
19	Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence. <i>Viruses</i> , 2022, 14, 187.	3.3	66
20	Recombination in Coronaviruses, with a Focus on SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1239.	3.3	65
21	Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. <i>Emerging Infectious Diseases</i> , 2021, 27, 2728-2731.	4.3	64
22	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0020021.	13.6	64
23	Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients. <i>Scientific Reports</i> , 2018, 8, 15490.	3.3	59
24	The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. <i>Drug Safety</i> , 2020, 43, 699-709.	3.2	56
25	Role of Hematopoietic Cells in the Maintenance of Chronic Human Torquetenovirus Plasma Viremia. <i>Journal of Virology</i> , 2010, 84, 6891-6893.	3.4	53
26	Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy. <i>Oncologist</i> , 2010, 15, 1214-1219.	3.7	51
27	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2136246.	5.9	50
28	Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy. <i>Emerging Infectious Diseases</i> , 2021, 27, 1249-1251.	4.3	47
29	Clioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsons, fenofibrate, and ribavirin. <i>Tumor Biology</i> , 2017, 39, 101042831769979.	1.8	45
30	Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus with implications for convalescent plasma therapy. <i>Reviews in Medical Virology</i> , 2021, 31, e2170.	8.3	45
31	Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Clinical Virology</i> , 2017, 94, 22-28.	3.1	44
32	Human Gyrovirus DNA in Human Blood, Italy. <i>Emerging Infectious Diseases</i> , 2012, 18, 956-959.	4.3	42
33	Anti-A isoagglutinin titres and SARS-CoV-2 neutralization: implications for children and convalescent plasma selection. <i>British Journal of Haematology</i> , 2020, 190, e148-e150.	2.5	42
34	Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: A clinical, neuroradiological and virological response after treatment with risperidone. <i>Antiviral Research</i> , 2007, 74, 156-158.	4.1	39
35	Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. <i>Critical Care</i> , 2020, 24, 331.	5.8	39
36	Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. <i>Antiviral Research</i> , 2022, 198, 105247.	4.1	39

#	ARTICLE	IF	CITATIONS
37	Zika Virus: Implications for Public Health. <i>Clinical Infectious Diseases</i> , 2016, 63, 227-233.	5.8	37
38	Changes In CD8+57+ T Lymphocyte Expansions After Autologous Hematopoietic Stem Cell Transplantation Correlate With Changes in Torquetenovirus Viremia. <i>Transplantation</i> , 2008, 85, 1867-1868.	1.0	35
39	The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2018, 53, 180-187.	2.4	35
40	Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1406-1410.	6.0	35
41	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	3.3	35
42	Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 29.	4.1	35
43	Transplantation of the Pancreas. <i>Current Diabetes Reports</i> , 2012, 12, 568-579.	4.2	31
44	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. <i>Viruses</i> , 2021, 13, 1594.	3.3	31
45	Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside. <i>Cells</i> , 2018, 7, 2.	4.1	30
46	The Role of Anti-HLA Antibodies in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1585-1588.	2.0	27
47	Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. <i>Lancet Haematology</i> , 2021, 8, e593-e604.	4.6	26
48	Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. <i>ERJ Open Research</i> , 2021, 7, 00713-2020.	2.6	25
49	COVID-19 convalescent plasma therapy: hit fast, hit hard!. <i>Vox Sanguinis</i> , 2021, 116, 935-942.	1.5	25
50	Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: Case report and review of literature. <i>Leukemia Research</i> , 2009, 33, 556-560.	0.8	24
51	Pancreas rejection after pandemic influenza virus A(H1N1) vaccination or infection : a report of two cases. <i>Transplant International</i> , 2011, 24, e28-e29.	1.6	24
52	Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. <i>Expert Review of Vaccines</i> , 2022, 21, 877-884.	4.4	24
53	Previous Humoral Immunity to the Endemic Seasonal Alphacoronaviruses NL63 and 229E Is Associated with Worse Clinical Outcome in COVID-19 and Suggests Original Antigenic Sin. <i>Life</i> , 2021, 11, 298.	2.4	23
54	CD57 Expression on Lymphoma Microenvironment As a New Prognostic Marker Related to Immune Dysfunction. <i>Journal of Clinical Oncology</i> , 2007, 25, 1289-1291.	1.6	22

#	ARTICLE	IF	CITATIONS
55	False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma. <i>Annals of Hematology</i> , 2008, 87, 343-344.	1.8	22
56	Progressive Multifocal Leukoencephalopathy: What's New?. <i>Neuroscientist</i> , 2010, 16, 308-323.	3.5	22
57	Induced pluripotent stem cells in hematology: current and future applications. <i>Blood Cancer Journal</i> , 2014, 4, e211-e211.	6.2	21
58	The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. <i>Life</i> , 2021, 11, 144.	2.4	21
59	Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy. <i>Emerging Infectious Diseases</i> , 2021, 27, 3180-3182.	4.3	21
60	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. <i>Medical Microbiology and Immunology</i> , 2019, 208, 253-258.	4.8	19
61	Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews. <i>Diagnostics</i> , 2021, 11, 1663.	2.6	19
62	Administering 25-hydroxyvitamin D3 in vitamin D-deficient young type 1A diabetic patients reduces reactivity against islet autoantigens. <i>Clinical Nutrition</i> , 2014, 33, 1153-1156.	5.0	18
63	Immunosuppressive monoclonal antibodies: current and next generation. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1759-1768.	6.0	17
64	Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. <i>Journal of Medical Virology</i> , 2022, 94, 491-498.	5.0	17
65	Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy. <i>Emerging Microbes and Infections</i> , 2021, 10, 2010-2015.	6.5	17
66	Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. <i>European Journal of Haematology</i> , 2021, 107, 24-28.	2.2	16
67	Introduction of SARS-CoV-2 C.37 (WHO VOI lambda) from Peru to Italy. <i>Journal of Medical Virology</i> , 2021, 93, 6460-6461.	5.0	16
68	Risperidone-induced reduction in JC viruria as a surrogate marker for efficacy against progressive multifocal leukoencephalopathy and hemorrhagic cystitis. <i>Journal of Clinical Virology</i> , 2007, 39, 63-64.	3.1	15
69	Three Paths to Better Tyrosine Kinase Inhibition Behind the Blood-Brain Barrier in Treating Chronic Myelogenous Leukemia and Glioblastoma with Imatinib. <i>Translational Oncology</i> , 2010, 3, 13-15.	3.7	15
70	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
71	Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. <i>Bone Marrow Transplantation</i> , 2007, 39, 811-812.	2.4	14
72	Polyomaviruses other than JCV are not detected in progressive multifocal leukoencephalopathy. <i>Journal of Clinical Virology</i> , 2009, 45, 161-162.	3.1	14

#	ARTICLE	IF	CITATIONS
73	Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 132-134.	0.4	14
74	An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1403-1414.	5.0	14
75	5-HT <sub>2A</sub> inhibitors for Progressive Multifocal Leukoencephalopathy: Old Drugs for an Old Disease. <i>Journal of Infectious Diseases</i> , 2008, 197, 328-328.	4.0	12
76	Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab. <i>Annals of Hematology</i> , 2010, 89, 519-522.	1.8	12
77	Torque teno virus monitoring in transplantation: The quest for standardization. <i>American Journal of Transplantation</i> , 2019, 19, 1599-1601.	4.7	12
78	COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103071.	1.0	12
79	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.	3.3	12
80	Reconstitution Rate of Absolute CD8+ T Lymphocyte Counts Affects Overall Survival After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 29-34.	0.6	11
81	What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 163-165.	6.0	11
82	Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naïve BNT162b2 vaccine recipients. <i>Vaccine</i> , 2021, 39, 2489-2490.	3.8	11
83	SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients. <i>Journal of Medical Virology</i> , 2021, 93, 5648-5649.	5.0	11
84	Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. <i>Hematological Oncology</i> , 2007, 25, 96-97.	1.7	10
85	Is a single COVID-19 vaccine dose enough in convalescents ?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2959-2961.	3.3	10
86	Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. <i>Vaccines</i> , 2022, 10, 94.	4.4	10
87	Passive immunotherapies for COVID-19: The subtle line between standard and hyperimmune immunoglobulins is getting invisible. <i>Reviews in Medical Virology</i> , 2022, 32, e2341.	8.3	10
88	Phenobarbital-Associated Bone Marrow Aplasia: A Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2008, 119, 18-21.	1.4	9
89	Effect of Induced Pluripotent Stem Cell Technology in Blood Banking. <i>Stem Cells Translational Medicine</i> , 2016, 5, 269-274.	3.3	9
90	Tweaking Mesenchymal Stem/Progenitor Cell Immunomodulatory Properties with Viral Vectors Delivering Cytokines. <i>Stem Cells and Development</i> , 2016, 25, 1321-1341.	2.1	9

#	ARTICLE	IF	CITATIONS
91	ABO Blood Group Correlations with Covid-19: Cohort Choice Makes A Difference. <i>Clinical Infectious Diseases</i> , 2021, 72, e919-e919.	5.8	9
92	The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. <i>International Journal of Infectious Diseases</i> , 2021, 102, 244-246.	3.3	9
93	COVID-19 infodemics: the role of mainstream and social media. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1568-1569.	6.0	9
94	Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing. <i>Annals of Internal Medicine</i> , 2021, 174, 1770-1772.	3.9	9
95	Convalescent plasma in outpatients with COVID-19. <i>Lancet Respiratory Medicine</i> , 2022, 10, 226-228.	10.7	9
96	Spike mutations in SARS-CoV-2 AY sublineages of the ΔDelta variant of concern: implications for the future of the pandemic. <i>Future Microbiology</i> , 2022, 17, 219-221.	2.0	9
97	Hyaluronate and risperidone for hemorrhagic cystitis. <i>Bone Marrow Transplantation</i> , 2007, 39, 57-57.	2.4	8
98	Re: Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized trials. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1288-1289.	6.3	8
99	Xenotropic murine leukaemia virus-related virus is not found in peripheral blood cells from treatment-naïve human immunodeficiency virus-positive patients. <i>Clinical Microbiology and Infection</i> , 2012, 18, 184-188.	6.0	8
100	Acquired factor XIII deficiency after desensitization as a potential contributor to postoperative bleeding: more than meets the eye. <i>Transplant International</i> , 2015, 28, 246-247.	1.6	8
101	Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?. <i>Vox Sanguinis</i> , 2022, 117, 641-646.	1.5	8
102	Smartphone Utilities for Infectious Diseases Specialists. <i>Clinical Infectious Diseases</i> , 2008, 47, 1234-1235.	5.8	7
103	Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: A report in a case of delayed graft failure. <i>Leukemia Research</i> , 2009, 33, 178-181.	0.8	7
104	Bone Marrow Aspiration and Biopsy. <i>New England Journal of Medicine</i> , 2010, 362, 182-183.	27.0	7
105	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. <i>Emerging Microbes and Infections</i> , 2021, 10, 710-712.	6.5	7
106	Is SARS-CoV-2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody-based therapeutics?. <i>Reviews in Medical Virology</i> , 2022, 32, e2314.	8.3	7
107	Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. <i>Viruses</i> , 2022, 14, 1443.	3.3	7
108	Gliptins. <i>Lancet</i> , 2007, 369, 269-270.	13.7	6

#	ARTICLE	IF	CITATIONS
109	Acute myeloid leukaemia after treatment with <sup>90</sup> Y-ibritumomab tiuxetan for follicular lymphoma. <i>Hematological Oncology</i> , 2008, 26, 179-181.	1.7	6
110	Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex. <i>Journal of Leukocyte Biology</i> , 2008, 84, 331-337.	3.3	6
111	Fatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantation. <i>Journal of Medical Virology</i> , 2009, 81, 857-860.	5.0	6
112	Cyclovirus Vietnam DNA in immunodeficient patients. <i>Journal of Clinical Virology</i> , 2016, 81, 12-15.	3.1	6
113	Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. <i>Clinical Microbiology and Infection</i> , 2021, 27, 987-992.	6.0	6
114	Urgent Need to Regulate Convalescent Plasma Differently from Thawed Plasma. <i>Transfusion Medicine and Hemotherapy</i> , 2021, 48, 132-133.	1.6	6
115	Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100097.	1.0	6
116	Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. <i>Haematologica</i> , 2007, 92, e96-e97.	3.5	5
117	Acute myeloid leukaemia. <i>Lancet, The</i> , 2007, 369, 367.	13.7	5
118	Long-term propylthiouracil use and acute myeloid leukemia: A case report and review of the literature. <i>Annals of Hematology</i> , 2008, 87, 233-235.	1.8	5
119	Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100016.	1.0	5
120	How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?. <i>Current Drug Targets</i> , 2017, 18, 811-825.	2.1	5
121	Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 531-546.	5.0	5
122	Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors. <i>Transfusion</i> , 2022, , .	1.6	5
123	Plasma Torquetenovirus (TTV) microRNAs and severity of COVID-19. <i>Virology Journal</i> , 2022, 19, 79.	3.4	5
124	Sialic acid moieties and 5-HT2a: Two faces of the same receptor for JC virus ?. <i>Journal of Clinical Virology</i> , 2008, 43, 132-133.	3.1	4
125	Does Contrast Enhancement Predict Survival in Progressive Multifocal Leukoencephalopathy?. <i>Journal of Infectious Diseases</i> , 2009, 199, 1410-1411.	4.0	4
126	Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: Clinical response after plasma exchange. <i>Transplant Immunology</i> , 2009, 21, 240-243.	1.2	4



#	ARTICLE	IF	CITATIONS
127	The role of bone marrow cells for JCV pathogenicity. <i>Journal of Clinical Virology</i> , 2009, 45, 230-231.	3.1	4
128	Cancer transmissibility across HLA barriers between immunocompetent individuals: Rare but not impossible. <i>Human Immunology</i> , 2011, 72, 1-4.	2.4	4
129	Association of donor-specific microchimerism with graft dysfunction in kidney transplant patients. <i>Transplant Immunology</i> , 2012, 26, 151-155.	1.2	4
130	Lack of usutu virus RNA in cerebrospinal fluid of patients with encephalitis of unknown etiology, Tuscany, Italy. <i>Journal of Medical Virology</i> , 2015, 87, 913-916.	5.0	4
131	Estimates of Ebola Virus Case-Fatality Ratio in the 2014 West African Outbreak. <i>Clinical Infectious Diseases</i> , 2015, 60, 829-829.	5.8	4
132	Lack of Marcellivirus DNA in immunocompetent and immunocompromised Italian patients. <i>Journal of Medical Virology</i> , 2020, 92, 187-190.	5.0	4
133	Torque teno virus microRNA detection in cerebrospinal fluids of patients with neurological pathologies. <i>Journal of Clinical Virology</i> , 2020, 133, 104687.	3.1	4
134	ABOâ€incompatible convalescent plasma transfusion: Yes, you can. <i>Transfusion Medicine</i> , 2021, 31, 215-216.	1.1	4
135	Kinetics of antiâ€SARSâ€COV2 spike protein IgG and IgA antibodies at 4Â°C: Implications for convalescent plasma stability. <i>Transfusion Medicine</i> , 2021, 31, 221-222.	1.1	4
136	SYMPTOMATIC SARS-CoV-2 INFECTIONS AFTER FULL SCHEDULE BNT162b2 VACCINATION IN SEROPOSITIVE HEALTHCARE WORKERS: A CASE SERIES FROM A SINGLE INSTITUTION. <i>Emerging Microbes and Infections</i> , 2021, 10, 1-6.	6.5	4
137	Convalescent plasma for COVID-19. TSUNAMI is not the final word. <i>European Journal of Internal Medicine</i> , 2022, 97, 116-118.	2.2	4
138	Safety and immunogenicity of synchronous COVID19 and influenza vaccination. <i>Journal of Clinical Virology Plus</i> , 2022, 2, 100082.	1.0	4
139	More on Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 2006, 355, 212-213.	27.0	3
140	An Inactivated Subvirion Influenza A (H5N1) Vaccine. <i>New England Journal of Medicine</i> , 2006, 354, 2724-2725.	27.0	3
141	Hypothesis: Central nervous system delivery of cyclosporine A for therapy of progressive multifocal leukoencephalopathy. <i>Journal of Clinical Virology</i> , 2007, 39, 156-158.	3.1	3
142	JC viremia and multiple sclerosis. <i>Journal of NeuroVirology</i> , 2008, 14, 85-86.	2.1	3
143	Ultrasound findings guided a successful hemicolectomy in a leukemic patient with neutropenic enterocolitis. <i>Journal of Ultrasound</i> , 2008, 11, 97-101.	1.3	3
144	Lymphotropic Polyomavirus and Progressive Multifocal Leukoencephalopathy. <i>Journal of Clinical Microbiology</i> , 2009, 47, 284-284.	3.9	3

#	ARTICLE	IF	CITATIONS
145	JC virus DNA in healthy brain tissue: A challenge for progressive multifocal leukoencephalopathy diagnosis. <i>Annals of Neurology</i> , 2009, 65, 230-230.	5.3	3
146	Human gyrovirus is not found in human CD34+ hematopoietic stem cells from peripheral blood or umbilical cord. <i>Journal of Clinical Virology</i> , 2013, 57, 182-183.	3.1	3
147	Cell therapies for treatment of human immunodeficiency virus infection. <i>Reviews in Medical Virology</i> , 2015, 25, 156-174.	8.3	3
148	Human Wharton's jelly-derived mesenchymal stromal cells engineered to secrete Epstein-Barr virus interleukin-10 show enhanced immunosuppressive properties. <i>Cytherapy</i> , 2016, 18, 205-218.	0.7	3
149	A CLUSTER OF SARS-CoV-2 DELTA VARIANT OF CONCERN ADDITIONALLY HARBORING F490S, NORTHERN LOMBARDY, ITALY. <i>International Journal of Infectious Diseases</i> , 2022, 116, 271-272.	3.3	3
150	Low prevalence of Gemycircularvirus DNA in immunocompetent and immunocompromised subjects. <i>New Microbiologica</i> , 2019, 42, 118-120.	0.1	3
151	Causes of Chronic Diarrhea. <i>New England Journal of Medicine</i> , 2006, 355, 1833-1834.	27.0	2
152	Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses. <i>Bone Marrow Transplantation</i> , 2007, 40, 1095-1096.	2.4	2
153	Treatment for elderly patients with multiple myeloma. <i>Lancet, The</i> , 2008, 371, 983-984.	13.7	2
154	Areas with high soil percolation by herbicides have higher incidence of low-grade non-Hodgkin lymphomas. <i>Annals of Hematology</i> , 2010, 89, 941-943.	1.8	2
155	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. <i>Leukemia and Lymphoma</i> , 2011, 52, 142-144.	1.3	2
156	Death of Healthy Volunteers and Professionals on Duty for Cadaveric Graft Shipment. <i>Transplantation</i> , 2011, 91, e79.	1.0	2
157	Attempt to classify the clinical impact of DNA viruses according to the ability to activate the innate immune system. <i>Journal of Medical Virology</i> , 2011, 83, 1060-1062.	5.0	2
158	Applications of Laparoscopic Robot-Assisted Surgery to Solid Organ Transplantations. <i>Transplantation</i> , 2012, 94, 695.	1.0	2
159	Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside. <i>International Reviews of Immunology</i> , 2016, 35, 351-368.	3.3	2
160	Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2186-2188.	2.4	2
161	Lack of neutralizing activity in nonconvalescent sera, regardless of ABO blood group and anti-A isoagglutinin titer. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100035.	1.0	2
162	Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?. <i>Vaccines</i> , 2022, 10, 406.	4.4	2

#	ARTICLE	IF	CITATIONS
163	Incubation period of human prion disease. <i>Lancet, The</i> , 2006, 368, 913-914.	13.7	1
164	Chaperonin 10 for rheumatoid arthritis. <i>Lancet, The</i> , 2006, 368, 1961.	13.7	1
165	Risk in drug trials. <i>Lancet, The</i> , 2006, 368, 2206.	13.7	1
166	Comment on "Germinal Center Helper T Cells Are Dual Functional Regulatory Cells with Suppressive Activity to Conventional CD4+ T Cells". <i>Journal of Immunology</i> , 2007, 179, 731.1-731.	0.8	1
167	Preemptive valganciclovir for cytomegalovirus infection in hematological patients. <i>Transplant Infectious Disease</i> , 2008, 10, 375-376.	1.7	1
168	Improving imatinib delivery to central nervous system. <i>Internal Medicine Journal</i> , 2010, 40, 318-319.	0.8	1
169	WU and KI Polyomaviruses Remain Orphans in Adults. <i>Journal of Infectious Diseases</i> , 2010, 201, 1276-1276.	4.0	1
170	Prophylactic Platelet Transfusions. <i>New England Journal of Medicine</i> , 2010, 362, 2140-2142.	27.0	1
171	Organ transplantation after cardiac death. <i>Lancet, The</i> , 2011, 377, 203-204.	13.7	1
172	Pretransplant Screening for Donor-Specific Antibodies and Graft Loss. <i>Transplantation</i> , 2011, 92, e15.	1.0	1
173	Fifth kidney transplantation in a patient with focal segmental glomerulosclerosis. <i>Transplant International</i> , 2013, 26, e19-e21.	1.6	1
174	ATG Brands and DSA. <i>American Journal of Transplantation</i> , 2014, 14, 737-737.	4.7	1
175	Potential Hurdles to ABO-Incompatible Living Donor Kidney Transplantation Without Augmented Immunosuppression. <i>American Journal of Transplantation</i> , 2015, 15, 1727.	4.7	1
176	Molecular validation of pathogen reduction technologies using rolling circle amplification coupled with real-time PCR for torquetenovirus DNA quantification. <i>Transfusion Medicine</i> , 2021, 31, 371-376.	1.1	1
177	SARS-CoV-2 and the safety of blood donations: Time for a brave revision?. <i>Transfusion</i> , 2022, 62, 717-719.	1.6	1
178	An inactivated subvirion influenza A (H5N1) vaccine. <i>New England Journal of Medicine</i> , 2006, 354, 2724-5; author reply 2724-5.	27.0	1
179	Lack of KIs virus DNA in plasma and cerebrospinal fluid in Italy. <i>New Microbiologica</i> , 2015, 38, 593-4.	0.1	1
180	Reflections after 2 years of COVID-19 pandemic. <i>Reviews in Medical Virology</i> , 2022, 32, e2351.	8.3	1

#	ARTICLE	IF	CITATIONS
181	High-Dose Convalescent Plasma for Treatment of Severe COVID-19. <i>Emerging Infectious Diseases</i> , 2022, 28, 1083-1083.	4.3	1
182	Concerns on unpredictable pharmacokinetics and pharmacodynamics of natalizumab. <i>Annals of Neurology</i> , 2010, 67, 270-270.	5.3	0
183	A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. <i>New England Journal of Medicine</i> , 2010, 362, 656-657.	27.0	0
184	Sustained Improvement of Cardiovascular Risk Factors (CVRF) and Cardiac Function in Type 1 Diabetic (T1D) Patients with Successful Pancreas Transplant Alone (PTA). <i>Transplantation</i> , 2012, 94, 696.	1.0	0
185	A Tale of Five Kidneys and One Heart Transplants. <i>Transplantation</i> , 2012, 94, 1080.	1.0	0
186	No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan. <i>Infection</i> , 2014, 42, 1065-1066.	4.7	0
187	CDC Crossmatch and C1qSCREEN in Liver Transplantation. <i>Transplantation</i> , 2014, 97, e61.	1.0	0
188	Endogenous anti-C1q antibodies do not interfere with the C1qScreen assay. <i>Tissue Antigens</i> , 2014, 83, 356-357.	1.0	0
189	Delayed cord clamping. <i>Lancet, The</i> , 2014, 384, 1668.	13.7	0
190	Getting the most from the Ebola vaccine success. <i>Vaccine</i> , 2015, 33, 7141.	3.8	0
191	The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 109-130.	0.1	0
192	Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?. <i>Annals of Translational Medicine</i> , 2019, 7, S298-S298.	1.7	0
193	COVID19 immune plasma donation after vaccination: pros and cons.. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103151.	1.0	0
194	Which Strain Will Finally Become Dominant?. <i>SpringerBriefs in Microbiology</i> , 2021, , 97-99.	0.1	0
195	Predicting the Functional Consequences of Mutations. <i>SpringerBriefs in Microbiology</i> , 2021, , 75-75.	0.1	0
196	Characterization of SARS-CoV-2 Variants. <i>SpringerBriefs in Microbiology</i> , 2021, , 73-74.	0.1	0
197	Whole Genome Mutation Rates. <i>SpringerBriefs in Microbiology</i> , 2021, , 9-10.	0.1	0
198	SARS-CoV-2 Variants. <i>SpringerBriefs in Microbiology</i> , 2021, , 55-71.	0.1	0

#	ARTICLE	IF	CITATIONS
199	Efficacy of Anti-Spike Vaccines and Monoclonal Antibodies Against SARS-CoV-2 Variants. SpringerBriefs in Microbiology, 2021, , 77-91.	0.1	0
200	“Beating the bushes” to identify previously unreported cases of a rare and potentially fatal adverse drug reaction: Comparison of HIV-negative rituximab-associated progressive multifocal leucoencephalopathy (PML) cases obtained by the Research on Adverse Drug Events and Report (RADAR), the FDA, the manufacturer, and a literature review. Journal of Clinical Oncology, 2009, 27, 6604-6604.	1.6	0
201	Inclusion of rituximab in standard chemotherapy regimens for non-Hodgkin's lymphomas and risk of progressive multifocal leucoencephalopathy.. Journal of Clinical Oncology, 2010, 28, e18541-e18541.	1.6	0
202	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ Naïve and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. Blood, 2016, 128, 1230-1230.	1.4	0
203	Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics. Life, 2022, 12, 614.	2.4	0
204	Performance Assessment of the LIAISON® SARS-CoV-2 Antigen Assay On Nasopharyngeal Swabs.. New Microbiologica, 2021, 44, .	0.1	0